Therapeutic treatment

• US 8,343,947 B2
• Filed: 03/17/2010
• Issued: 01/01/2013
• Est. Priority Date: 07/15/2003
• Status: Expired due to Fees

• Current Assignee: Jallal Messadek
• Original Assignee: Jallal Messadek
• Inventors: Messadek, Jallal
• Primary Examiner(s): SZNAIDMAN, MARCOS L
• Application Number:
  US12/726,109
• Publication Number:
  US 20100210608A1
• Time in Patent Office: 1,021 Days
• Field of Search: 514/175, 514/578
• US Class Current: 514/175
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 31/616 by carboxylic acids, e.g. acetylsalicylic acid
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/10 Antioedematous agents; Diuretics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

The invention describes the use of betaine for treating and preventing arterites. The invention also describes an orally administered composition for treating arterites and, in particular, intermittent claudication, said composition containing, as an active ingredient, an active therapeutic quantity of betaine glycine by single dose. The invention particularly describes a medicament provided for treating a patient suffering from an intermittent claudication caused by peripheral circulatory disorders such as arteriosclerosis obliterans or by thromboangiitis obliterans.

Claims

1. A method for increasing the absolute claudication distance in a patient suffering of intermittent claudication or peripheral arterial disease with intermittent claudication, said method comprising administering to said patient, as a therapeutically active agent for increasing the maximal walking distance, a composition comprising as a single active ingredient a therapeutically effective amount of at least one therapeutically active compound selected from the group consisting of betaine of formula (CH₃)₃N⁺(CH₂)COO⁻

, pharmaceutically active salts thereof and mixtures thereof, so as to increase said absolute claudication distance.

2. The method of claim 1, wherein the absolute claudication distance of said patient is increased by at least 10% with respect to the average walking distance of said patient before his treatment, said 10% increase corresponding to at least 20 meters and wherein the walking distance is determined by assessing the patient using a constant-load treadmill testing at a 12% grade inclination and speed of 3.2 km/h.

3. The method of claim 1, in which a therapeutically effective amount of at least one therapeutically active compound selected from the group consisting (CH₃)₃N⁺(CH₂)COO⁻

, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient for at least 4 weeks.

4. The method of claim 1, in which an effective therapeutic amount of at least one therapeutically active compound selected from the group consisting of (CH₃)₃N⁺(CH₂) COO⁻

, pharmaceutically active salts thereof and mixtures thereof is orally administered to said patient.

5. The method of claim 1, in which the therapeutically active compound selected from the group consisting of (CH₃)₃ N⁺(CH₂)COO⁻

, pharmaceutically active salts thereof and mixtures thereof is administered to said patient with a dosage form selected from the group consisting of the once daily administration forms and the twice daily administration forms.

6. The method of claim 1, in which the therapeutically active compound selected from the group consisting of (CH₃)₃N⁺(CH₂)COO⁻

, pharmaceutically active salts thereof and mixtures thereof is administered to said patient with an extended release dosage form.

7. The method of claim 1, in which at least 1000 mg of the therapeutically active compound selected from the group consisting of (CH₃)₃N⁺(CH₂)COO⁻

, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an immediate release dosage form.

8. The method of claim 1, in which at least 250 mg of the therapeutically active compound selected from the group consisting of (CH₃)₃N⁺(CH₂) COO⁻

, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an extended release dosage form.

9. The method of claim 1, in which from 250 mg to 3000 mg of the therapeutically active compound selected from the group consisting of (CH₃)₃N⁺(CH₂)COO⁻

, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an extended release dosage form.

10. The method of claim 1, in which from 250 mg to 1000 mg of the therapeutically active compound selected from the group consisting of (CH₃)₃N⁺(CH₂)COO⁻

, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an extended release dosage form.

11. The method of claim 1, in which at least 250 mg of the therapeutically active compound selected from the group consisting of (CH₃)₃N⁺(CH₂)COO⁻

, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an extended release dosage form, and at least 250 mg of the therapeutically active compound selected from the group consisting of (CH₃)₃N⁺(CH₂)COO⁻

, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as an immediate release dosage form.

12. The method of claim 1, wherein said therapeutically active compound selected from the group consisting of (CH₃)₃N⁺(CH₂)COO⁻

, pharmaceutically active salts thereof and mixtures thereof is daily administered to said patient as at least one unit dosage comprising an immediate release dosage portion of at least 250 mg of the therapeutically active compound and an extended release dosage portion of at least 250 mg of the therapeutically active compound.